Table 4.
Multiparametric Cox regression results for the entire cohort, and for the moderate- and high-vascular groups, analyzing the combined correlation between the MGMT methylation status and the number of adjuvant Temozolomide-cycles with the overall survival.
| Covariables | HR [95% CI] MGMT |
p-Value |
|---|---|---|
| Entire cohort | ||
| MGMT status | 1.53 [0.96, 2.43] | 0.0727 |
| TMZ cycles | 0.78 [0.70, 0.85] | <0.0001 * |
| Moderate rCBV | ||
| MGMT status | 1.75 [1.08, 4.20] | 0.0416 * |
| TMZ cycles | 0.78 [0.66, 0.90] | <0.0001 * |
| High rCBV | ||
| MGMT | 1.03 [0.56, 1.92] | 0.9121 |
| TMZ cycles | 0.77 [0.68, 0.87] | <0.0001 * |
* Significant p-values: < 0.05.